Recon: Novartis plans thousands of job cuts in global restructuring; FDA lifts hold on Gilead blood cancer trials

ReconReconBiologicsBiotechnologyDiagnosticsGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy